Idiopathic Interstitial Pneumonias 2018
DOI: 10.1183/13993003.congress-2018.pa2941
|View full text |Cite
|
Sign up to set email alerts
|

Prognosis of pulmonary fibrosis with usual interstitial pneumonia pattern in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-related nephritiss

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Patients on the antifibrotic drug nintedanib may have reduced incidence of AE-IPF (22), supporting cross-talk between acute inflammatory responses and chronic fibrosis, but no specific therapies have yet proven effective in their treatment. Repeated sub-acute injury to alveolar epithelial cells is also likely to drive chronic decline in IPF (23,24), where diffuse alveolar damage can be seen without clinical evidence of an acute exacerbation (25).…”
Section: Introductionmentioning
confidence: 99%
“…Patients on the antifibrotic drug nintedanib may have reduced incidence of AE-IPF (22), supporting cross-talk between acute inflammatory responses and chronic fibrosis, but no specific therapies have yet proven effective in their treatment. Repeated sub-acute injury to alveolar epithelial cells is also likely to drive chronic decline in IPF (23,24), where diffuse alveolar damage can be seen without clinical evidence of an acute exacerbation (25).…”
Section: Introductionmentioning
confidence: 99%